Pharmacyclics: Difference between revisions
Attach Financial status year 2013 |
|||
| Line 18: | Line 18: | ||
| production = |
| production = |
||
| services = |
| services = |
||
| revenue = {{increase}} {{US$|235 million}} {{small|(2013)}}<ref name="Pharm">{{Cite web|url = https://www1.hkexnews.hk/listedco/listconews/sehk/2020/0427/2020042701439.pdf|title = Shangri-La Hotels and Resorts Annual report 2019-20 |date= |website=Shangri-La Hotels and Resorts |publisher = Shangri-La Hotels and Resorts Asia |access-date= |url-status=live}}</ref> |
|||
| revenue = |
|||
| operating_income = |
| operating_income = {{increase}} {{US$|110 million}} {{small|(2013)}}<ref name="Pharm" /> |
||
| net_income = {{increase}} {{US$|86.1 million}} {{small|(2013)}}<ref name="Pharm" /> |
|||
| net_income = |
|||
| assets = {{increase}} {{US$|1.06 billion}} {{small|(2013)}}<ref name="Pharm" /> |
|||
| assets = |
|||
| equity = {{increase}} {{US$|829 million}} {{small|(2013)}}<ref name="Pharm" /> |
|||
| equity = |
|||
| owner = |
| owner = |
||
| num_employees = |
| num_employees = |
||
Revision as of 13:58, 28 August 2020
| Company type | Subsidiary |
|---|---|
| Nasdaq: PCYC | |
| Industry | Biopharmaceutical |
| Founded | 1991 |
| Founders | Jonathan Sessler, Richard A. Miller[1] |
| Headquarters | Sunnyvale, California |
Area served | Worldwide |
Key people | Robert Duggan, former CEO and Chairman |
| Revenue |  US$235 million (2013)[2] |
| US$110 million (2013)[2] | |
| US$86.1 million (2013)[2] | |
| Total assets | US$1.06 billion (2013)[2] |
| Total equity | US$829 million (2013)[2] |
| Parent | AbbVie |
| Website | pharmacyclics |
Pharmacyclics LLC is an American biopharmaceutical company based in Sunnyvale, California. It is primarily focused on the development of cancer therapies.[3][4] In 2017, Xynomic Pharmaceuticals acquired all global rights to Abexinostat, Pharmacyclics' primary commercial product.[5]
Acquisition by AbbVie
In March 2015, Chicago-based biopharmaceutical firm AbbVie announced it would acquire Pharmacyclics, as well as its lead anti-cancer compound ibrutinib (Imbruvica) for $21 billion. As part of the deal, AbbVie will pay $261.25 per share in a mixture of both cash and AbbVie equity.[6] The merger is expected to close in mid-2015.[7]
Duggan will receive over $3.55 billion from the sale of Pharmacyclics to AbbVie in "one of the biggest paydays ever from the buyout of a publicly held company."[8][9][10][11][12]
As CEO and Chairman of Pharmacyclics since 2008, Robert Duggan has opted not to receive compensation from the company.[13][8]
References
- ^ Lee Clippard (2006). "Professor's personal battle leads to development of new cancer drug". University of Texas. Retrieved May 30, 2015.
- ^ a b c d e "Shangri-La Hotels and Resorts Annual report 2019-20" (PDF). Shangri-La Hotels and Resorts. Shangri-La Hotels and Resorts Asia.
{{cite web}}: CS1 maint: url-status (link) - ^ Sawyer, Anthony (25 January 2018). "Pharmacyclics (PCYC) Given Daily Media Impact Score of 0.42". Week Herald. Retrieved 29 January 2018.
- ^ "Pharmacyclics Inc. (PCYC)". Yahoo. Retrieved May 30, 2015.
- ^ "Xynomic Acquires Global Rights to Anticancer Drug Abexinostat". Genetic Engineering & Biotechnology News. February 24, 2017. Retrieved February 25, 2017.
- ^ Staff (5 March 2015). "AbbVie Acquires Oncology Drug Firm Pharmacyclics for $21B". Genetic Engineering & Biotechnology News.
- ^ https://www.sec.gov/Archives/edgar/data/949699/000119312515079014/d885940dex991.htm
- ^ a b "The $3.55 billion Man". America's Markets.
- ^ Antoine Gara. "Robert Duggan". Forbes.
- ^ "Pharmacyclics May Soon Be Acquired by Johnson & Johnson for $18 Billion". Science Times.
- ^ "The Hiring Guru: Robert Duggan Billionaire". The Huffington Post.
- ^ Sean Williams (27 February 2013). "This Is One Incredible CEO". fool.com.
- ^ Gary Strauss (March 24, 2015). "The $3.55 billion Man". USA Today. Retrieved May 29, 2015.
External links
- Official website
- Historical business data for Pharmacyclics:
- SEC filings